热门话题-受<a href="https://laohu8.com/S/NVS">诺华</a>业绩影响，UCB股价下跌
4月28日 - ** 比利时制药公司UCB UCB.BR股价下跌约4.4%，此前诺华 NOVN.S 公布了令人失望的季度业绩 (link)，而投资者对UCB近期收购Neurona一事仍持谨慎态度 (link)
** KBC证券的梅卡尔（Jacob Mekhael）表示，诺华的银屑病药物Cosentyx（UCB明星药物Bimzelx的竞争对手）的销售额“并不令人印象深刻”
** Degroof Petercam的塞纳夫（David Seynaevve）指出，Cosentyx的表现“加剧了市场对Bimzelx可能不得不提供更高折扣的担忧，即使需求上升，也会对营收产生负面影响”
** 塞纳夫补充道，“收购Neurona的反响并不理想”，并指出风险在于Neurona的癫痫治疗方案仍处于相当实验性的阶段
** “市场总体上对细胞疗法持负面态度，迄今为止发展之路颇为艰难，”梅卡尔表示，尽管两位分析师仍持乐观态度，并指出该疗法与UCB的癫痫药物组合存在协同效应
** 截至周一收盘，UCB股价4月累计下跌约9.4%，表现逊于同期下跌约3.2%的欧洲医疗保健指数.SXDE
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.